PPI-2458
DRACPC ID DRACPC0082
Active Ingredients PPI-2458
Description A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class.
Synonyms MetAP-2 Inhibitor PPI-2458; Methionine Aminopeptidase 2 Inhibitor PPI-2458; PPI-2458
Type Small Molecule
Disease Lymphoma, Solid tumors
Classification
MetAP-2 Inhibitor Amino acid and derivative
Structure Information
Molecular Formula C22H36N2O6
Molecular Weight 424.5
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-1-amino-3-methyl-1-oxobutan-2-yl)carbamate
InChI InChI=1S/C22H36N2O6/c1-12(2)7-8-15-21(5,30-15)18-17(27-6)14(9-10-22(18)11-28-22)29-20(26)24-16(13(3)4)19(23)25/h7,13-18H,8-11H2,1-6H3,(H2,23,25)(H,24,26)/t14-,15-,16-,17-,18-,21+,22+/m1/s1
InChI_Key QBDVVYNLLXGUGN-XGTBZJOHSA-N
SMILES O=C(N[C@@H](C(N)=O)C(C)C)O[C@H]1[C@H]([C@@]([C@@]2(C)O[C@@H]2C/C=C(C)/C)([H])[C@@]3(CC1)OC3)OC
External Codes
PubChem CID 6918653
DrugBank Accession Number DB05864
NCI Thesaurus Code C38129
UNII NA0Y2SRR29 GSRS
CAS 431077-35-9
Drug approval
Drug indication
Investigated for use/treatment in lymphoma (non-hodgkin's) and solid tumors.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00100347 | A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors | Non-Hodgkin's Lymphoma; Solid Tumors | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
